HeimCOH • ASX
Cochlear Ltd
281,41 $
27. sep., 19:00:00 GMT+10 · AUD · ASX · Lagalegir fyrirvarar
HlutabréfSkráð hlutabréf í AUHöfuðstöðvar: AU
Við síðustu lokun
284,21 $
Dagbil
281,01 $ - 284,99 $
Árabil
237,69 $ - 350,31 $
Markaðsvirði
18,43 ma. AUD
Meðalmagn
199,23 þ.
V/H-hlutf.
51,83
A/V-hlutfall
1,46%
Aðalkauphöll
ASX
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(AUD)jún. 2024Breyting á/á
Tekjur
568,55 m.8,20%
Rekstrarkostnaður
305,05 m.5,74%
Nettótekjur
82,70 m.4,03%
Hagnaðarhlutfall
14,55-3,83%
Hagnaður á hvern hlut
EBITDA
126,20 m.16,26%
Virkt skatthlutfall
26,42%
Heildareignir
Heildarskuldir
(AUD)jún. 2024Breyting á/á
Reiðufé og skammtímafjárfestingar
513,60 m.-7,54%
Heildareignir
2,75 ma.6,87%
Heildarskuldir
904,60 m.10,33%
Eigið fé alls
1,84 ma.
Útistandandi hlutabréf
65,49 m.
Eiginfjárgengi
10,11
Arðsemi eigna
11,42%
Ávöxtun eigin fjár
15,04%
Breyting á handbæru fé
(AUD)jún. 2024Breyting á/á
Nettótekjur
82,70 m.4,03%
Handbært fé frá rekstri
115,85 m.-15,22%
Reiðufé frá fjárfestingum
-28,95 m.-44,39%
Reiðufé frá fjármögnun
-73,20 m.26,69%
Breyting á handbæru fé
14,20 m.-15,98%
Frjálst peningaflæði
83,96 m.23,15%
Um
Cochlear is a medical device company that designs, manufactures, and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant. Based in Sydney, Cochlear was formed in 1981 as a subsidiary of Nucleus with finance from the Australian government to commercialise the implants pioneered by Dr. Graeme Clark, although the company later became separate. As of 2022, the company holds 50% of the cochlear implant market, with more than 250,000 people receiving one of Cochlear's implants as of 2015. Cochlear was named Australia's most innovative company by the Intellectual Property Research Institute of Australia in 2002 and 2003, and one of the world's most innovative companies by Forbes in 2011. Wikipedia
Framkvæmdastjóri
Stofnsett
1981
Vefsvæði
Starfsfólk
5.047
Leit
Hreinsa leit
Loka leit
Google forrit
Aðalvalmynd